Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients

Journal of Medical Economics

Volumn 15, Issue 2, 2012, Pages 332-339

  Carter, Chureen T ^a   Changolkar, Arun K ^b   Scott McKenzie, R ^a  

^a Janssen Scientific Affairs LLC   (United States)

^b SOAL PharmaTech Solutions   (United States)

Author keywords

Anti tumor necrosis factor; Costs; Managed care; Utilization

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SELF ADMINISTRATION; DRUG UTILIZATION; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMORBIDITY; DRUG UTILIZATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; PRESCRIPTION FEES; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84858114899     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.649325     Document Type: Article

References (40)

1. Humira (adalimumab) [package insert]. North Chicago, IL: Abbott Laboratories, 2009
2. Enbrel (etanercept) [package insert]. Thousand Oaks, CA: Immunex Corporation, 2009
3. Remicade (infliximab) [package insert]. Horsham, PA: Centocor Ortho Biotech Inc, 2010
4. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008;148:124-34 (Pubitemid 351651555)
5. Bullano MF, McNeeley BJ, Yu YF, et al. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. Manag Care Interface 2006;19:47-53 (Pubitemid 44476656)
6. Wu E, Chen L, Birnbaum H, et al. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. Curr Med Res Opin 2007;23:1749-59 (Pubitemid 47300371)
7. Daniel GW, McNeeley B, Huang X, et al. Dosing patterns and health plan costs among RA patients treated with tumor necrosis factor antagonists. Poster presented at: American College of Rheumatology; San Francisco, CA; October 24-29, 2008
8. Kievit W, Adang EM, Fransen J, et al. The effectiveness and medication costs of three anti-tumour necrosis factor a agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008;67: 1229-34
9. Schabert VF, Watson C, Gandra SR, et al. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. J Med Econ. 2012;15: published online 25 November 2011, doi:10.3111/13696998.2011.644645
10. Stockl K, Jarrar M, Tandon N. Dosing patterns of anti-TNF therapy in patients with rheumatoid arthritis in a managed care setting. Dis Manag Health Outcomes 2004;12:189-96 (Pubitemid 38845096)
11. Braid MJ, Ziskind M, Tandon N. Infliximab dosing and cost analysis of Medicare rheumatoid arthritis patients. Poster presented at: The European League Against Rheumatism; Vienna, Austria; June 8-11, 2005
12. Abarca J, Malone DC, Armstrong EP, et al. Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit. J Manag Care Pharm 2004;10:538-42
13. Wu E, Chen L, Birnbaum H, et al. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin 2008;24:2229-40
14. Nair KV, Tang B, Van Den Bos J, et al. Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially-insured and Medicare-eligible populations. Curr Med Res Opin 2009;25:303-14
15. Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther 2011;33:901-13
16. Koncz T, Pentek M, Brodszky V, et al. Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin Biol Ther 2010;10:1367-78
17. PharMetrics LifeLink Health Plan Database. PharMetrics, Inc. Watertown, MA: IMS Health, 2010
18. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83 (Pubitemid 17055592)
19. Medstat Disease Staging Software Version 5.24. Ann Arbor, MI: Thomson Medstat Inc, 2006
20. Gonnella JS, Louis DZ, Gozum MV, et al, eds. Disease staging: clinical criteria. Ann Arbor, MI: The MEDSTAT Group, Inc, 2003
21. Ollendorf DA, Lidsky L. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting. Am J Ther 2006;13:502-6 (Pubitemid 44813679)
22. Stern R, Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 2004;31:1538-45 (Pubitemid 39006634)
23. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003;9(6 Suppl):S136-43 (Pubitemid 37345201)
24. Yazici Y, Krasnokutsky S, Barnes JP, et al. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol 2009;36:907-13
25. Lajas C, Abasolo L, Bellajdel B, et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 2003; 49:64-70 (Pubitemid 36286131)
26. Michaud K, Messer J, Choi HK, et al. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 2003;48:2750-62 (Pubitemid 37280602)
27. Rahman MU, Strusberg I, Geusens P, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66:1233-38 (Pubitemid 47309743)
28. Durez P, Van den Bosch F, Corluy L, et al. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology (Oxford) 2005;44:465-8 (Pubitemid 41511135)
29. van Vollenhoven RF, Brannemark S, Klareskog L. Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis 2004;63:426-30 (Pubitemid 38453310)
30. Sidiropoulos P, Bertsias G, Kritikos HD, et al. Infliximab treatment for rheumatoid arthritis, with dose titration based on disease activity score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis 2004;63:144-8 (Pubitemid 38122132)
31. Flendrie M, Creemers MCW, van Riel PLCM. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. Rheumatology (Oxford) 2007;46:146-9 (Pubitemid 44932803)
32. Ariza-Ariza R, Navarro-Sarabia F, Herná ndez-Cruz B, et al. Dose escalation of the anti-TNF-a agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford) 2007;46:529-32 (Pubitemid 46344670)
33. Gilbert Jr. TD, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2004;5:36
34. Ollendorf DA, Massarotti E, Birbara C, et al. Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 2005;11:383-93
35. Tang B, Rahman M, Waters HC, et al. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 2008;30:1375-84
36. Weycker D, Yu EB, Woolley JM, et al. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged-65 years with rheumatoid arthritis. Clin Ther 2005;27:646-56 (Pubitemid 40835976)
37. Ollendorf DA, Klingman D, Hazard E, et al. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther 2009;31:825-35
38. Effective Healthcare: Rheumatoid Arthritis Medicines. A guide for adults. Agency for Healthcare Research and Quality. Consumer summary guide. Rockville, MD: AHRQ Publication Number 08-EHC004-2A, 2008
39. Gabriel SE, Crowson CS, O'Fallon WM. A comparison of two comorbidity instruments in arthritis. J Clin Epidemiol 1999;52:1137-42 (Pubitemid 29535413)
40. Navarro-Cano G, del Rincó n I, Pogosian S, et al. Association of mortality with disease severity in rheumatoid arthritis, independent of comorbidity. Arthritis Rheum 2003;48:2425-33 (Pubitemid 37129419)